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Purpose	  of	  review:	  
Following	  solid	  organ	  transplantation	  (SOT),	  populations	  of	  donor	  lymphocytes	  are	  
frequently	  found	  in	  the	  recipient	  circulation.	  Their	  impact	  on	  host	  alloimmunity	  has	  long	  
been	  debated	  but	  remains	  unclear,	  and	  it	  has	  been	  suggested	  that	  transferred	  donor	  
lymphocytes	  may	  either	  promote	  tolerance	  to	  the	  graft,	  or	  hasten	  its	  rejection.	  We	  discuss	  
possible	  mechanisms	  by	  which	  the	  interaction	  of	  donor	  passenger	  lymphocytes	  with	  
recipient	  immune	  cells	  may	  either	  augment	  the	  host	  alloimmune	  response,	  or	  inhibit	  it.	  
	  
Recent	  findings:	  
Recent	  work	  has	  highlighted	  that	  donor	  T	  lymphocytes	  are	  the	  most	  numerous	  of	  the	  donor	  
leukocyte	  populations	  within	  a	  SOT	  and	  that	  these	  may	  be	  transferred	  to	  the	  recipient	  after	  
transplantation.	  Surprisingly,	  graft-­‐versus-­‐host	  recognition	  of	  major	  histocompatibility	  class	  
II	  on	  host	  B	  cells	  by	  transferred	  donor	  CD4	  T	  cells	  can	  result	  in	  marked	  augmentation	  of	  host	  
humoral	  alloimmunity	  and	  lead	  to	  early	  graft	  failure.	  Killing	  of	  donor	  CD4	  T	  cells	  by	  host	  NK	  
cells	  is	  critical	  in	  preventing	  this	  augmentation.	  	  
	  
Summary:	  
The	  ability	  of	  passenger	  donor	  CD4	  T	  cells	  to	  effect	  long-­‐term	  augmentation	  of	  the	  host	  
humoral	  alloimmune	  response	  raises	  the	  possibility	  that	  ex-­‐vivo	  treatment	  or	  modification	  
of	  the	  donor	  organ	  prior	  to	  implantation	  may	  improve	  long-­‐term	  transplant	  outcomes.	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In	  solid	  organ	  transplantation	  (SOT),	  the	  delivery	  of	  passenger	  donor	  lymphocytes	  (DLs)	  to	  
recipients	  is	  almost	  unavoidable.	  Passenger	  lymphocytes	  have	  been	  detected	  in	  the	  
recipient's	  circulation	  within	  the	  first	  two	  hours	  following	  murine	  liver	  1;	  primate	  kidney	  2;	  
and	  human	  liver	  transplantation	  3,4.	  The	  presence	  of	  DLs	  can	  be	  associated	  with	  graft	  versus	  
host	  disease	  (GVHD),	  passenger	  lymphocyte	  syndrome,	  or	  may	  possibly	  induce	  tolerance.	  
The	  impact	  of	  transfer	  of	  DLs	  will	  likely	  be	  determined	  by:	  the	  microenvironment	  of	  the	  
transplanted	  organ;	  migration	  and	  sensitisation	  status	  of	  DLs;	  and	  the	  capacity	  for	  
interaction	  with	  host	  immune	  constituents,	  as	  recently	  reviewed	  5.	  
Organs	  such	  as	  the	  small	  intestines	  and	  lungs	  represent	  the	  first	  physiological	  mucosal	  
defence	  barrier	  and	  possess	  large	  numbers	  of	  graft-­‐resident	  lymphocytes.	  The	  generally	  
poor	  long-­‐term	  outcomes	  associated	  with	  these	  organs	  may	  be	  attributed	  to	  the	  
simultaneous	  transfer	  of	  DLs	  contained	  within	  the	  allograft	  upon	  transplantation	  6.	  Tissue-­‐
resident	  lymphocytes	  have	  been	  a	  particular	  research	  focus	  recently,	  but	  the	  role	  of	  this	  
subset	  in	  SOT	  has	  yet	  to	  be	  clarified.	  This	  review	  will	  first	  describe	  the	  make-­‐up	  of	  the	  tissue-­‐
resident	  lymphocyte	  populations	  that	  are	  likely	  to	  be	  present	  within	  an	  allograft.	  We	  will	  
then	  discuss	  how	  these	  populations	  may	  contribute	  to	  graft	  tolerance	  and	  rejection,	  before	  
considering	  how	  strategies	  that	  specifically	  target	  DLs	  may	  be	  used	  to	  prolong	  graft	  survival.	  	  
Passenger	  lymphocytes	  populations	  within	  an	  allograft.	  
The	  nature	  of	  tissue-­‐resident	  lymphocytes	  differs	  in	  lineage	  and	  phenotype	  and	  includes	  B	  
cells	  7,	  CD8+	  8	  9,	  FoxP3+	  10,11,	  innate	  γδ	  12,13,	  NK	  T	  cells	  14	  15	  and	  CD4	  T	  cells	  16.	  These	  have	  
been	  reported	  in	  various	  tissues	  such	  as	  the	  skin,	  gut,	  lungs,	  kidney,	  and	  liver.	  To	  what	  
extent	  these	  populations	  remain	  resident	  within	  the	  allograft	  or	  egress	  to	  the	  recipient’s	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circulation	  is	  not	  yet	  known,	  but	  is	  clearly	  an	  important	  distinction	  –	  those	  DLs	  that	  migrate	  
to	  the	  recipient’s	  secondary	  lymphoid	  tissue	  will	  presumably	  have	  greater	  influence	  on	  host	  
alloimmunity.	  In	  this	  respect,	  this	  review	  will	  focus	  on	  donor	  B	  cells	  and	  CD4+	  T	  cells,	  
because	  their	  potential	  for	  migration	  and	  interaction	  with	  host	  immune	  constituents	  
suggests	  the	  greatest	  capacity	  for	  shaping	  the	  alloimmune	  response.	  	  
Passenger	  donor	  B	  lymphocytes	  in	  allograft	  rejection	  and	  tolerance.	  
Although	  not	  as	  prominent	  feature	  as	  T	  lymphocytes,	  circulating	  donor	  –strain	  B	  
lymphocytes	  (dnB	  cells)	  are	  frequently	  detectable	  in	  recipients	  of	  solid	  organ	  transplants,	  
particularly	  following	  liver	  and	  intestinal	  transplantation	  17.	  Appreciable	  numbers	  are	  also	  
released	  into	  the	  circuit	  during	  ex	  vivo	  normothermic	  perfusion	  of	  porcine	  kidneys	  18.	  How	  
such	  transfer	  impacts	  upon	  the	  host	  alloimmune	  response	  remains	  unclear.	  Most	  
immediately,	  migrating	  dnB	  cells	  will	  deliver	  MHC	  class	  I	  and	  class	  II	  alloantigen,	  and	  could	  
potentially	  prime	  cytotoxic	  CD8	  T	  cell	  and	  direct-­‐pathway	  CD4	  T	  cell	  alloresponses	  in	  the	  
recipient.	  However,	  resting	  B	  cells	  do	  not	  generally	  express	  sufficient	  co-­‐stimulatory	  ligands	  
for	  activation	  of	  naïve	  T	  cells	  19-­‐21,	  and	  indeed,	  have	  been	  targeted	  as	  a	  possible	  therapeutic	  
strategy	  in	  autoimmunity	  22,	  raising	  the	  possibility	  that	  transferred	  dnB	  cells	  may	  inhibit	  the	  
host	  response	  against	  the	  graft.	  Against	  this,	  activated	  23,24	  or	  memory	  25,26	  B	  cells	  are	  
effective	  antigen	  presenting	  cells	  for	  driving	  naïve	  T	  cell	  activation,	  and	  it	  seems	  likely	  that	  
even	  if	  transferred	  as	  naïve	  cells,	  exposure	  to	  previously	  unencountered	  recipient	  antigen	  
within	  the	  inflammatory	  environment	  of	  the	  graft	  27,	  will	  lead	  to	  full	  B	  cell	  activation.	  In	  
support,	  recent	  murine	  studies	  have	  reported	  a	  positive	  role	  for	  passenger	  dnB	  cells	  in	  
triggering	  recipient	  CD4	  T	  cell	  alloimmunity	  28,	  although	  the	  impact	  was	  relatively	  modest	  
when	  compared	  with	  the	  contribution	  from	  transferred	  donor	  dendritic	  cells.	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One	  striking	  manifestation	  of	  the	  transfer	  of	  dnB	  cells	  is	  Passenger	  Lymphocyte	  Syndrome,	  
in	  which	  haemolysis	  is	  triggered	  by	  donor	  B	  cell	  recognition	  of	  mismatched	  ABO	  blood	  group	  
antigens	  in	  the	  recipient	  29.	  Whether	  this	  relates	  to	  transfer	  of	  plasma	  cells	  or	  to	  B	  cells	  that	  
undergo	  further	  differentiation	  to	  antibody	  secretors	  within	  the	  recipient	  is	  not	  known,	  but	  
the	  latter	  is	  suggested	  by	  a	  recent	  report	  highlighting	  similar	  donor-­‐derived	  antibody	  
profiles	  in	  a	  pair	  of	  recipients	  from	  the	  same	  deceased	  kidney	  donor	  30.	  The	  recipient	  
antibody	  responses	  observed	  with	  Passenger	  Lymphocyte	  Syndrome	  appear	  transient,	  
presumably	  because	  transferred	  donor	  plasma	  cells	  are	  not	  deposited	  in	  an	  appropriate	  
recipient	  niche	  to	  facilitate	  long-­‐term	  survival,	  and	  it	  is	  therefore	  doubtful	  that	  they	  
contribute	  to	  allograft	  rejection,	  particularly	  because	  transfer	  of	  responsiveness	  against	  
donor	  human	  leukocyte	  antigen	  HLA	  antigen	  would	  be	  highly	  unusual.	  	  
Several	  recent	  clinical	  studies	  have	  suggested	  that	  a	  state	  of	  operational	  tolerance	  is	  
associated	  with	  a	  signature	  B	  cell	  phenotype	  31-­‐33,	  with	  an	  expanded	  transitional	  B	  cell	  
population.	  Although	  suppressor	  function	  has	  not	  been	  confirmed	  in	  the	  clinical	  setting,	  this	  
is	  consistent	  with	  development	  of	  regulatory	  B	  cells	  34,	  and	  B	  cells	  have	  been	  shown	  to	  be	  
important	  mediators	  of	  tolerance	  in	  murine	  transplant	  models	  35.	  It	  is	  generally	  assumed	  
that	  the	  putative	  regulatory	  B	  cell	  population	  is	  of	  recipient	  origin,	  and	  is	  seems	  unlikely,	  
given	  their	  presentation	  of	  mismatched	  MHC	  class	  I	  and	  class	  II	  alloantigens,	  that	  donor	  B	  
cells	  would	  survive	  sufficiently	  long	  in	  the	  recipient	  to	  provide	  regulatory	  function.	  However,	  
although	  poorly	  understood,	  regulatory	  B	  cell	  development	  is	  favoured	  by	  an	  inflammatory	  
environment	  36,37,	  and	  requires	  positive	  signalling	  via	  the	  B	  cell	  receptor,	  CD40	  and	  TLR	  
ligation	  38.	  Thus	  although	  not	  yet	  demonstrated,	  Interactions	  with	  host	  T	  cells	  and	  antigen	  
presenting	  cells	  could	  conceivably	  provide	  the	  appropriate	  triggers	  for	  differentiation	  of	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migrating	  passenger	  donor	  B	  lymphocytes	  into	  regulatory	  cells	  that	  promote	  allograft	  
survival.	  	  
Passenger	  donor	  T	  lymphocytes	  in	  allograft	  rejection	  and	  tolerance	  
The	  most	  abundant	  lymphocyte	  subset	  contained	  within	  a	  SOT	  is	  likely	  to	  be	  the	  CD8	  and	  
CD4	  T	  cell	  16,18.	  Although	  these	  may	  be	  naïve	  circulating	  T	  cells	  that	  are	  trapped	  within	  the	  
graft	  microcirculation,	  additional	  populations	  of	  memory	  lymphocytes	  within	  the	  graft	  
parenchyma	  (so	  called	  tissue	  resident	  memory	  (TRM)	  lymphocytes)	  are	  also	  likely	  to	  be	  
transferred	  (5,39).	  Transfer	  of	  donor	  T	  lymphocytes	  (dnT	  cells)	  is	  most	  readily	  manifest	  by	  the	  
development	  of	  graft	  versus	  host	  disease	  in	  the	  recipient40,41.	  	  
One	  might	  anticipate	  that	  GVH	  responses	  mediated	  by	  dnT	  cell	  transfer	  would	  favour	  
enhanced	  allograft	  survival,	  by	  inhibiting	  host	  alloreactivity	  through	  cytotoxic	  destruction	  of	  
host	  antigen	  presenting	  cells	  and	  alloreactive	  lymphocyte	  subsets.	  Our	  studies	  of	  mouse	  
chronic	  heart	  allograft	  rejection	  however	  highlighted	  that	  in	  the	  MHC	  class	  II	  mismatched	  
‘bm12’	  to	  C57BL/6	  model,	  a	  key	  component	  of	  the	  rejection	  response	  was	  the	  triggering	  of	  
recipient	  anti-­‐nuclear	  autoantibody	  responses	  42,43.	  These	  responses	  were	  class-­‐switched,	  
but	  surprisingly,	  T	  cell	  help	  for	  their	  initiation	  was	  provided,	  not	  by	  recipient	  CD4	  T	  cells,	  but	  
by	  donor	  CD4	  T	  cells.	  The	  potential	  contribution	  of	  autoimmunity	  to	  allograft	  rejection	  is	  
increasingly	  emphasised	  (reviewed	  in	  44-­‐46)	  and	  T	  cell	  depletion	  experiments	  suggested	  a	  
direct	  role	  for	  the	  autoantibody	  response	  observed	  in	  our	  model	  in	  mediating	  progression	  of	  
allograft	  vasculopathy	  42,47.	  	  
Autoantibody	  responses	  did	  not	  develop	  in	  mice	  that	  selectively	  lacked	  MHC	  class	  II	  
expression	  only	  on	  B	  cells,	  highlighting	  that	  cognate	  interaction	  between	  the	  dnCD4	  T	  cell	  
and	  host	  B	  cell	  was	  the	  direct	  trigger	  for	  initiating	  humoral	  autoimmunity.	  This	  raises	  the	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question	  as	  to	  the	  precise	  MHC	  II	  /	  peptide	  complex	  that	  was	  recognised	  on	  the	  surface	  of	  
the	  host	  B	  cells,	  and	  in	  this	  regard	  it	  was	  notable	  that	  the	  entire	  follicular	  B	  cell	  population	  
up-­‐regulated	  MHC	  class	  II	  and	  costimulatory	  ligand	  expression,	  in	  keeping	  with	  global	  
activation47.	  Further	  experiments	  incorporating	  T	  cell	  deficient	  recipients	  highlighted	  that	  
the	  critical	  step	  for	  recipient	  B	  cells	  differentiation	  to	  an	  antibody-­‐secreting	  cell	  was	  
concurrent	  BCR	  ligation	  with	  target	  antigen47.	  This	  reflects	  the	  peculiarities	  of	  direct-­‐
pathway	  allorecognition,	  in	  which	  as	  much	  as	  5%	  of	  an	  individual’s	  T	  cell	  repertoire	  
recognises	  intact	  MHC	  alloantigen	  48-­‐50	  .	  Consequently,	  the	  dnCD4	  T	  cell	  fraction	  is	  likely	  to	  
recognise	  the	  majority,	  if	  not	  all,	  MHC	  class	  II	  complexes	  on	  host	  B	  cells,	  irrespective	  of	  the	  
particular	  peptide	  bound	  in	  the	  binding	  groove.	  Thus,	  the	  dnCD4	  T	  cells	  provide	  permissive	  
help	  to	  all	  B	  cells;	  antibody	  secretion	  is	  determined	  instead	  by	  availability	  of	  target	  antigen	  
(figure	  1a).	  Presumably,	  the	  autoantibody	  responses	  observed	  in	  our	  experiments	  reflect	  
activation	  of	  anergic	  autoreactive	  B	  cells	  that	  are	  already	  bound	  via	  their	  BCR	  to	  target	  
autoantigen.	  	  
An	  intriguing	  possibility	  raised	  by	  this	  unusual,	  ‘peptide-­‐degenerate’	  help	  is	  that	  dnCD4	  T	  
cells	  can	  provide	  help	  to	  recipient	  B	  cells	  for	  the	  production	  of	  alloantibody	  against	  
alloantigenic	  determinants	  expressed	  on	  the	  surface	  of	  the	  dnCD4	  T	  cell	  (figure	  1b).	  This	  
occurs	  despite	  those	  CD4	  T	  cells	  clearly	  being	  tolerant	  to	  that	  antigen	  when	  encountered	  
restricted	  to	  self	  in	  the	  donor	  51.	  We	  further	  showed	  that	  the	  provoked	  alloantibody	  
response	  resulted	  in	  rapid	  lysis	  of	  dnCD4	  T	  cell	  fraction;	  effectively	  the	  dnCD4	  T	  cells	  actively	  
promote	  their	  own	  destruction.	  This	  further	  suggests	  that	  passenger	  CD4	  T	  cells	  within	  the	  
transplant	  could	  contribute	  to	  graft	  rejection.	  This	  was	  tested	  by	  developing	  a	  murine	  model	  
of	  chronic	  heart	  allograft	  rejection	  in	  which	  the	  donor	  ‘bm12.Kd.IE’	  strain	  differed	  from	  the	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C57BL/6	  recipient	  at	  additional	  MHC	  class	  I	  (H-­‐2Kd)	  and	  class	  II	  (I-­‐Ed	  and	  I-­‐Abm12)	  loci.	  Heart	  
grafts	  were	  rejected	  slowly,	  with	  the	  development	  of	  progressive	  allograft	  vasculopathy	  that	  
was	  associated	  with	  robust	  alloantibody	  responses	  directed	  against	  the	  mismatched	  class	  I	  
and	  class	  II	  alloantigens.	  Critically,	  alloantibody	  responses	  were	  markedly	  reduced	  in	  
recipients	  of	  heart	  grafts	  from	  T-­‐cell	  depleted	  donors,	  as	  were	  recipient	  cytotoxic	  CD8	  T	  cell	  
alloimmune	  and	  indirect-­‐pathway	  CD4	  T	  cell	  responses.	  Heart	  allografts	  from	  T	  cell	  deficient	  
donors	  exhibited	  markedly	  reduced	  allograft	  vasculopathy	  51,	  thus	  confirming	  an	  important	  
role	  for	  passenger	  dnCD4	  T	  cells	  in	  augmenting	  host	  alloimmunity.	  
Although	  these	  findings	  would	  appear	  to	  shift	  emphasis	  from	  the	  recipient	  alloreactive	  CD4	  
T	  cell	  population	  as	  the	  central	  mediator	  of	  allograft	  rejection,	  it	  was	  notable	  that	  rejection	  
was	  still	  dependent	  upon	  the	  recipient	  CD4	  T	  cell	  fraction.	  Our	  ongoing	  work	  suggests	  that	  
recipient	  CD4	  T	  cells	  are	  required	  for	  provision	  of	  essential	  T	  follicular	  helper	  cell	  function	  
that	  maintains	  long-­‐lasting	  germinal	  centre	  alloantibody	  responses:	  although	  dnCD4	  T	  cells	  
could	  still	  trigger	  recipient	  humoral	  immunity	  in	  T	  cell	  deficient	  recipients,	  germinal	  centre	  
responses	  did	  not	  develop	  and	  heart	  grafts	  survived	  indefinitely	  without	  development	  of	  
allograft	  vasculopathy47.	  Thus	  optimal	  recipient	  effector	  humoral	  responses	  required	  
collaboration	  between	  donor	  and	  recipient	  CD4	  T	  cell	  fractions	  (figure	  1c).	  	  
The	  model	  we	  employed	  was	  undoubtedly	  developed	  to	  facilitate	  examination	  of	  the	  
potential	  contribution	  of	  dnCD4	  T	  cells	  to	  graft	  rejection,	  and	  could	  be	  justly	  criticised	  as	  
lacking	  immediate	  clinical	  relevance.	  What	  therefore	  are	  the	  likely	  implications	  of	  our	  
findings	  to	  clinical	  transplantation?	  First,	  our	  models	  were	  characterised	  by	  relatively	  limited	  
MHC	  mismatch	  between	  the	  donor	  and	  recipient	  and	  the	  ability	  of	  donor	  CD4	  T	  cells	  to	  
interact	  productively	  with	  the	  recipient	  B	  cell	  population	  was	  dependent	  upon	  avoidance	  of	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rapid	  destruction	  by	  host	  NK	  cell	  recognition.	  Notably,	  in	  a	  completely	  MHC-­‐mismatched	  
(BALB/c	  to	  C57BL/6)	  model	  of	  chronic	  alloantibody	  mediated	  rejection,	  augmentation	  of	  the	  
host	  alloantibody	  response	  by	  passenger	  CD4	  T	  cells	  only	  occurred	  upon	  depletion	  of	  the	  
recipient	  NK	  cell	  population.	  Such	  depletion	  resulted	  in	  rapid	  (acute)	  graft	  rejection	  51.	  The	  
role	  of	  host	  NK	  cells	  in	  graft	  rejection	  remains	  controversial	  52,	  and	  our	  findings	  highlight	  an	  
important,	  and	  previously	  unappreciated,	  role	  for	  NK	  cells	  in	  preventing	  graft	  rejection	  
through	  recognition	  of	  donor	  passenger	  lymphocytes.	  Killer	  cell	  Immunoglobulin-­‐like	  
receptor	  (KIR)	  recognition	  is	  complex	  and	  still	  only	  partly	  understood	  53,	  but	  current	  MHC	  
matching	  practices	  in	  clinical	  renal	  transplantation	  will	  result	  in	  approximately	  half	  of	  donor	  
–	  recipient	  combinations	  being	  matched	  at	  KIR	  loci	  54,	  thereby	  enabling	  donor	  passenger	  
lymphocytes	  to	  avoid	  rapid	  NK-­‐cell	  mediated	  destruction.	  Whether	  this	  results	  in	  poorer	  
long-­‐term	  allograft	  survival	  is	  not	  known,	  because	  studies	  that	  have	  examined	  the	  role	  of	  NK	  
cells	  in	  clinical	  graft	  rejection	  have	  generally	  studied	  MHC-­‐matched	  donor	  /	  recipient	  
combinations	  to	  avoid	  the	  confounding	  impact	  of	  adaptive	  HLA	  allorecognition54,55	  whereas	  
the	  impact	  of	  NK	  cell	  recognition	  observed	  in	  our	  model	  is	  dependent	  upon	  donor	  /	  
recipient	  MHC	  class	  II	  mismatching.	  Avoidance	  of	  NK	  cell	  killing	  does	  not,	  however,	  
guarantee	  long-­‐term	  survival	  of	  the	  donor	  CD4	  T	  cell	  fraction;	  as	  mentioned	  above,	  the	  
donor	  CD4	  T	  cell	  fraction	  was	  still	  killed	  rapidly	  (within	  one	  week	  of	  transplantation)	  by	  the	  
adaptive	  alloimmune	  responses	  that	  they	  provoke	  in	  the	  host.	  This	  illustrates	  that	  short-­‐
lived	  immune	  interactions	  that	  occur	  in	  the	  peri-­‐transplant	  period	  may	  have	  long-­‐lasting	  
consequences;	  despite	  their	  rapid	  destruction,	  the	  impact	  of	  donor	  CD4	  T	  cells	  on	  
augmenting	  host	  humoral	  alloimmunity	  was	  evident	  many	  weeks	  after	  transplantation.	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Most	  solid	  organs	  are	  now	  known	  to	  harbour	  populations	  of	  resident	  memory	  T	  (TRM)	  
lymphocytes	  (reviewed	  in	  56),	  which	  are	  phenotypically	  distinct	  from	  the	  central	  and	  effector	  
memory	  subsets.	  Donor-­‐derived	  TRM	  lymphocytes	  will	  presumably	  be	  transferred	  within	  
most	  solid	  organ	  allografts,	  yet	  their	  contribution	  to	  host	  alloimmunity	  is	  not	  known	  5,	  39.	  
Although	  our	  experiments	  did	  not	  distinguish	  between	  TRM	  lymphocytes	  within	  graft	  
parenchyma	  and	  naïve	  circulating	  T	  cells	  caught	  in	  the	  graft	  microcirculation,	  they	  do	  
nevertheless	  suggest	  a	  potential	  mechanism	  by	  which	  transferred	  donor	  TRM	  cells	  may	  
influence	  the	  host	  alloimmune	  response.	  In	  this	  respect,	  it	  was	  notable	  that	  heart	  allografts	  
from	  donors	  that	  had	  been	  primed	  six	  weeks	  earlier	  by	  a	  recipient	  strain	  skin	  graft	  (thus	  
generating	  anti-­‐recipient	  memory	  responses)	  provoked	  stronger	  alloantibody	  responses	  and	  
were	  rejected	  much	  more	  rapidly	  than	  heart	  grafts	  from	  naïve	  donors	  47,51.	  	  
Our	  results	  suggest	  that	  strategies	  that	  deplete	  passenger	  donor	  lymphocytes	  within	  the	  
allograft	  may	  hold	  potential	  to	  prolong	  allograft	  survival.	  This	  could	  possibly	  be	  achieved	  by	  
performing	  ex	  vivo	  normothermic	  perfusion	  of	  the	  organ	  after	  retrieval;	  an	  approach	  that	  is	  
gaining	  popularity	  because	  of	  its	  potential	  to	  ‘recondition’	  the	  organ	  and	  improve	  viability	  
57.	  Early	  reports	  suggest	  that	  substantial	  numbers	  of	  donor	  T	  lymphocytes	  are	  recovered	  
from	  the	  circuit	  during	  the	  ex-­‐vivo	  perfusion	  phase	  18,	  and	  that	  would	  otherwise	  be	  released	  
into	  the	  recipient’s	  circulation.	  
Before	  such	  strategies	  are	  attempted,	  however,	  it	  is	  worth	  considering	  whether	  resident	  
donor	  lymphocytes	  could	  provide	  protective	  function	  and	  promote	  graft	  survival.	  This	  has	  
not	  been	  studied,	  but	  mucosal	  TRM	  cells	  provide	  an	  important	  first-­‐line	  defence	  against	  
tissue	  re-­‐infection,	  and	  are	  likely	  involved	  in	  maintaining	  cytomegalovirus	  (CMV)	  latency	  58-­‐
60.	  Deletion	  of	  donor	  TRM	  within	  an	  allograft	  could	  therefore	  possibly	  exacerbate	  the	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intragraft	  inflammatory	  milieu	  due	  to	  CMV	  re-­‐activation,	  which	  may	  in	  turn	  provoke	  host	  
alloimnunity	  and	  increase	  the	  incidence	  of	  allograft	  rejection	  61.	  	  
In	  addition	  to	  TRM	  lymphocytes,	  there	  is	  increasing	  evidence	  supporting	  a	  distinct	  population	  
of	  tissue-­‐resident	  regulatory	  T	  cells	  62.	  These	  are	  thought	  to	  regulate	  local	  responses	  within	  
the	  organ	  and	  suppress	  development	  of	  autoimmunity	  –	  T	  cell	  receptor	  sequencing	  suggests	  
skewing	  towards	  recognition	  of	  self-­‐antigen	  63,64.	  Persistence	  of	  tissue-­‐resident	  donor	  
regulatory	  T	  cells	  after	  transplantation	  could	  conceivably	  favour	  allograft	  survival,	  through,	  
for	  example,	  production	  of	  suppressor	  cytokines,	  such	  as	  IL-­‐10	  and	  TGF-­‐β,	  that	  promote	  an	  
anti-­‐inflammatory	  environment	  within	  the	  allograft.	  This	  has	  not	  been	  tested,	  but	  resonates	  
with	  the	  growing	  appreciation	  that	  local	  immune	  events	  within	  the	  graft	  shape	  the	  
recipient’s	  alloimmune	  response	  65,66,	  and	  parallels	  the	  observation	  that	  recipient	  regulatory	  
T	  cells	  mediate	  suppression	  principally	  within	  the	  allograft	  67,68.	  	  
Finally,	  similar	  to	  the	  peptide-­‐degenerate,	  graft-­‐versus-­‐host	  recognition	  of	  recipient	  MHC	  
class	  II	  complexes	  by	  donor-­‐strain	  CD4	  T	  effector	  cells,	  passenger	  donor	  CD4	  T	  regulatory	  
cells	  may	  also	  interact	  with	  a	  large	  proportion	  of	  the	  recipient	  B	  cell	  population.	  This	  
interaction	  would	  instead,	  however,	  be	  expected	  to	  profoundly	  inhibit	  host	  humoral	  
immunity	  (figure	  1d).	  In	  support,	  bm12	  heart	  allografts	  from	  donors	  that	  have	  been	  
depleted	  of	  regulatory	  T	  cells	  (by	  administering	  anti-­‐CD25	  mAb	  to	  the	  bm12	  donor	  prior	  to	  
heart	  allograft	  rejection)	  are	  rejected	  much	  more	  rapidly	  by	  C56BL/6	  recipients	  than	  heart	  
grafts	  from	  unmodified	  bm12	  donors	  (unpublished	  data,	  GJP).	  	  
Conclusions	  
Many	  different	  subsets	  of	  donor	  lymphocytes	  are	  likely	  to	  be	  transferred	  to	  the	  recipient	  
within	  a	  solid	  allograft.	  Ex	  vivo	  perfusion	  studies	  suggest	  that	  the	  T	  lymphocyte	  subset	  is	  the	  
12	  
	  
most	  numerous	  and	  is	  readily	  released	  into	  the	  recipient’s	  circulation.	  Whether	  this	  reflects	  
release	  of	  circulating	  T	  cells	  that	  have	  been	  trapped	  within	  the	  graft	  microcirculation	  or	  
mobilisation	  of	  TRM	  cells	  from	  graft	  parenchyma	  has	  yet	  to	  be	  determined,	  but	  is	  likely	  an	  
important	  distinction.	  Our	  work	  has	  highlighted	  one	  potential	  mechanism	  by	  which	  donor	  
CD4	  T	  cell	  interaction	  with	  the	  recipient	  B	  cell	  population	  augments	  the	  host	  alloimmune	  
response,	  as	  most	  dramatically	  demonstrated	  by	  the	  accelerated	  rejection	  of	  murine	  heart	  
allografts	  from	  donors	  that	  have	  primed	  against	  recipient.	  A	  testable	  clinical	  consequence	  of	  
this	  observation	  is	  that	  kidney	  transplants	  from	  living	  donors	  sensitised	  against	  recipient	  
(typically	  mother	  to	  offspring)	  may	  be	  associated	  with	  higher	  rates	  of	  rejection	  than	  normal.	  	  	  
	  
Key	  points	  
-­‐ Transfer	  of	  passenger	  donor	  lymphocytes	  is	  common	  after	  solid	  organ	  
transplantation	  
-­‐ Transferred	  passenger	  donor	  CD4	  T	  cells	  can	  potentially	  interact	  productively	  with	  
recipient	  B	  cells	  for	  long-­‐lasting	  augmentation	  of	  the	  host	  alloimmune	  response.	  
-­‐ This	  augmentation	  is	  more	  pronounced	  if	  memory	  donor	  CD4	  T	  cells	  with	  
specificity	  for	  recipient	  are	  transferred.	  	  
-­‐ Host	  NK	  cell	  recognition	  and	  destruction	  of	  passenger	  lymphocytes	  is	  critical	  for	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  Heading:	  Peptide-­‐degenerate	  interactions	  between	  donor	  CD4	  T	  cells	  an	  recipient	  B	  cells.	  
Legend:	  a)	  Top	  panel:	  i)	  Donor	  CD4	  T	  cells	  TCR	  recognise	  the	  majority	  of,	  if	  not	  all,	  MHC	  class	  
II	  complexes	  expressed	  on	  recipient	  B	  cells	  as	  foreign,	  regardless	  of	  the	  loaded	  peptide.	  This	  
‘peptide-­‐degenerate’	  recognition	  results	  in	  global	  activation	  of	  all	  recipient	  B	  cells.	  Recipient	  
B	  cells	  differentiation	  into	  antibody-­‐secreting	  plasma	  cells	  is,	  however,	  determined	  by	  the	  
concurrent	  BCR	  ligation	  to	  target	  antigen;	  hence,	  different	  antibody	  specificities	  are	  
generated	  depending	  upon	  antigen	  availability.	  This	  includes	  recognition	  of	  self	  antigen	  for	  
development	  of	  autoantibody	  (ii).	  
b)	  Donor	  CD4+	  T	  cells	  expressing	  alloantigenic	  determinants	  can	  provide	  help	  to	  recipient	  B	  
cells	  for	  production	  of	  alloantibody	  directed	  against	  alloantigen	  determinants	  expressed	  on	  
the	  donor	  T	  cells.	  This	  alloantibody	  can,	  in	  turn,	  result	  in	  lysis	  of	  the	  donor	  CD4	  T	  cells.	  
c)	  Although	  donor	  CD4	  T	  cells	  trigger	  recipient	  B	  cell	  activation	  and	  plasma	  cell	  
differentiation,	  germinal	  center	  responses	  are	  not	  observed	  unless	  secondary	  involvement	  
of	  a	  population	  of	  recipient-­‐derived	  T	  follicular	  helper	  T	  cells.	  This	  potentially	  results	  in	  
deposition	  of	  high-­‐affinity	  long-­‐lived	  plasma	  cells	  in	  bone	  marrow	  and	  generation	  of	  
memory	  B	  cells.	  PD-­‐1,	  programmed	  death-­‐1;;	  PD-­‐1L,	  programmed	  death-­‐1	  ligand;	  SAP,	  
SLAM-­‐associated	  protein.	  	  
d)	  Peptide-­‐degenerate	  suppression	  by	  passenger	  donor	  regulatory	  CD4	  T	  cells	  may	  inhibit	  
alloreactive	  B	  cell	  activation,	  by	  counteracting	  positive	  ‘peptide-­‐specific’’	  signalling	  provided	  
by	  alloreactive	  recipient	  CD4	  helper	  T	  cells.	  BCR,	  B	  cell	  receptor;	  MHC,	  major	  
histocompatibility	  complex;	  SLAM,	  Signaling	  lymphocytic	  activation	  molecule;	  TCR,	  T	  cell	  
receptor.	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